AV¶ÌÊÓƵ

2022/09 - 2023/06

SUITE A LA SITUATION COVID, LES SEMINAIRES EN PRESENTIELS NE SONT OUVERTS QU'AUX COLLABORATEURS DU DEPARTEMENT PATIM (Y COMPRIS AFFILIES CLINIQUES). SI VOUS SOUHAITEZ NOUS REJOINDRE PAR ZOOM, MERCI DE SUIVRE LE LIEN INDIQUE SUR LE FACMED HEBDOMADAIRE.

Reverse translationalÌýdendritic cells-based immunotherapy vs. T cell-hostile tumours: A tug of war!

12h15-13h00

Auditoire Franceschetti
C150

TDB

TDB

TBD

12h15-13h00

Auditoire JL Reverdin
B02.2526

Pr Brant Isakson
AV¶ÌÊÓƵ of Virginia, School of medicine
Charlottesville, USA

An unexpected role for Pannexin 3 in cardiovascular disease

ÌýBrenda Kwak

TBD

12h15-13h00

TBD

Sophia Qiqun ZENG
Opna Bio SA, Lausanne

Neural signaling/molecular in cancer progression

ÌýBrenda KwakÌý

12h15-13h00

Pr. Roberto Speck
Universitatsspital (Zurich)

Unprecedented anti-HIV activity of macrophages in HIV-infected iHMD-NSG mice

Karl-Heinz Krause

12h15-13h00

B04.2222 (CMU)

Dr. Stefano Sammicheli
Ichnos Sciences (Lausanne)

A drug is born: preclinical development of ISB 1442, a first in class CD38 X CD47 bispecific innate cell engager

ÌýSimone Becattini

12h15-13h00

Pr Jerome Tamburini
CRTOH, UniGe CMU

CEBPA confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia.

ÌýJulien Bertrand

12h15-13h00

Pr Nikolai Klymiuk
Technical AV¶ÌÊÓƵ of Munich

Exploring the immune system in pig models for biomedical research

ÌýÌýJ. Seebach

Pr. Tim Halim
Cancer Research, AV¶ÌÊÓƵ ofÌýCambridge (UK)

Immune regulatory functions of ILC2

12h15-13h00

A. Renold (CMU)

ÌýPr. Aranxta Tabernero
AV¶ÌÊÓƵ of Salamanca

A Src inhibitory peptide based on connexin43 as a therapy for glioblastoma

Brenda Kwak

Dr. Alexandre Boissonnas
CIMI-Paris, Hopital Pitié-Salpétrière

Pr. Fabio Zampieri
AV¶ÌÊÓƵ of Padua, Medical School(Italy)

Pr. Maria Casanova-Acebes
CNIO, Madrid

Christoph Scheiermann